FIELD: pharmaceuticals.
SUBSTANCE: invention relates to novel antibody-drug conjugates (ADCs) containing an antibody that binds to DLK1, or an antigen-binding fragment thereof, and a pharmaceutical composition containing the said conjugates for the prevention or treatment of cancer associated with DLK1 expression.
EFFECT: obtaining antibody-drug conjugates including antibody against human DLK1.
59 cl, 1 dwg, 3 tbl, 3 ex
Title | Year | Author | Number |
---|---|---|---|
ANTI-LILRB1 ANTIBODY AND ITS USE | 2020 |
|
RU2801535C1 |
PROGRAMMED CELL DEATH (PD-1) PROTEIN-1 ANTIBODIES AND USE THEREOF | 2017 |
|
RU2725950C1 |
SPECIFIC TO MUCIN-1 POLYPEPTIDE AND ITS USE | 2021 |
|
RU2805840C1 |
NEW ANTI-C-MET-ANTIBODY AND APPLICATION THEREOF | 2018 |
|
RU2751720C2 |
ANTIBODIES AGAINST TIGIT AND APPLICATION THEREOF | 2019 |
|
RU2750705C1 |
FGF21 FUSED WITH LONG-ACTING PROTEINS AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 2016 |
|
RU2741087C2 |
ANTI-CEACAM1 ANTIBODY AND ITS APPLICATION | 2018 |
|
RU2754876C2 |
COMPOSITION FOR PREVENTION AND TREATMENT OF SKIN DISEASE CONTAINING SUBSTANCE SPECIFICALLY BINDING WITH VIMENTINE DERIVATIVE PEPTIDE | 2018 |
|
RU2751486C1 |
ANTIBODIES AGAINST VISTA AND APPLICATION THEREOF | 2018 |
|
RU2750723C1 |
MULTIFUNCTIONAL MULTI-SPECIFIC MULTIMERIC BIOMOLECULAR POLYMER WITH PROLONGED IN VIVO EFFICIENCY | 2020 |
|
RU2805307C1 |
Authors
Dates
2023-08-11—Published
2020-03-05—Filed